- Report
- January 2026
- 180 Pages
Global
From €4002EUR$4,500USD£3,436GBP
- Report
- February 2026
- 200 Pages
Global
From €7106EUR$7,990USD£6,101GBP
- Report
- August 2026
- 132 Pages
Global
From €4225EUR$4,750USD£3,627GBP
- Report
- September 2025
- 150 Pages
Global
From €3958EUR$4,450USD£3,398GBP
- Report
- December 2024
- 30 Pages
Global
From €2446EUR$2,750USD£2,100GBP
- Report
- June 2025
- 147 Pages
Global
From €3513EUR$3,950USD£3,016GBP
- Report
- January 2023
- 167 Pages
Global
From €3202EUR$3,600USD£2,749GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,216USD£3,110GBP
- Report
- January 2024
- 114 Pages
United States
€3113EUR$3,500USD£2,672GBP
- Report
- January 2024
- 156 Pages
United States
€3380EUR$3,800USD£2,901GBP
- Report
- January 2024
- 109 Pages
United States
€3113EUR$3,500USD£2,672GBP
- Report
- February 2018
- 680 Pages
Global
From €19566EUR$22,000USD£16,798GBP
Trelegy Ellipta is a combination inhaler used to treat chronic obstructive pulmonary disease (COPD). It contains three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. The inhaler is designed to reduce inflammation in the airways, relax the muscles around the airways, and help keep the airways open. Trelegy Ellipta is a long-term maintenance treatment for COPD and is not intended for the relief of acute symptoms.
The Trelegy Ellipta market is a subset of the larger respiratory drugs market. It is composed of a variety of products, including inhalers, nebulizers, and other treatments. These products are used to treat a range of respiratory conditions, including asthma, COPD, and cystic fibrosis.
Some of the companies in the Trelegy Ellipta market include GlaxoSmithKline, AstraZeneca, Novartis, and Boehringer Ingelheim. These companies produce a variety of respiratory drugs, including Trelegy Ellipta, and are involved in research and development of new treatments. Show Less Read more
